2.
Treatment effects in the liraglutide vs. glimepiride (previous metformin monotherapy subgroup only) and liraglutide vs. sitagliptin studies
| Liraglutide vs. glimepiride | Liraglutide vs. sitagliptin | |||||
|---|---|---|---|---|---|---|
| Risk factor | Liraglutide 1.2 mg + metformin n = 91 | Liraglutide 1.8 mg + metformin n = 83 | Sulphonylurea + metformin n = 89 | Liraglutide 1.2 mg + metformin n = 214 | Liraglutide 1.8 mg + metformin n = 211 | Sitagliptin 100 mg + metformin n = 210 |
| Change in HbA1c (mmol/mol) (%) | −13.7 (11.2) | −14.2 (10.8) | −12.7 (10.6) | −13.1 (11.0) | −16.4 (9.7) | −10.0 (11.6) |
| −1.25 (1.02) | −1.30 (0.99) | −1.16 (0.97) | −1.24 (1.04) | −1.50 (0.89) | −0.90 (1.04) | |
| Change in systolic blood pressure (mmHg) | −3.33 (12.90) | −1.18 (12.70) | 2.26 (12.65) | −0.55 (13.23) | −0.72 (13.14) | −0.94 (13.17) |
| Change in total cholesterol (mmol/l)* | −0.02 (0.82) | −0.30 (0.80) | 0.09 (0.08) | −0.03 (0.82) | −0.17 (0.80) | −0.02 (0.80) |
| Change in LDL-C (mmol/l)* | 0.15 (0.68) | 0.13 (0.67) | 0.22 (0.67) | 0.08 (0.69) | 0.05 (0.67) | 0.13 (0.68) |
| Change in HDL-C (mmol/l)* | 0.02 (0.21) | −0.03 (0.20) | −0.02 (0.20) | 0.00 (0.17) | 0.00 (0.17) | 0.00 (0.17) |
| Change in triglycerides (mmol/l)* | −0.44 (1.29) | −0.26 (1.26) | −0.25 (1.26) | −0.19 (1.42) | −0.43 (1.37) | −0.40 (1.38) |
| Change in BMI (kg/m2) | −0.64 (0.95) | −0.75 (1.11) | 0.48 (3.69) | −1.00 (0.08) | −1.18 (0.08) | −0.34 (0.08) |
| Major hypo event rate (per 100 patient years) | 0 | 0 | 0 | 1 | 0 | 0 |
| Minor hypo event rate (per 100 patient years) | 4.9 | 17.1 | 217.2 | 17.8 | 16.1 | 10.6 |
Data are mean (sd).
*
The model accepts values in mg/dl. The following factors have been used to convert to mmol/l: 0.0259 for total cholesterol, LDL-C and HDL-C, and 0.0113 for triglycerides.